Hesperos, Inc., a leader in human biology modeling for drug development through its Human-on-a-Chip® technology, is excited to announce the appointment of Lawrence (Larry) Florin as Chief Executive Officer. With over 20 years of leadership experience in bio and clinical technology, Mr. Florin has a strong background in clinical development, business growth, and strategic innovation.
Before joining Hesperos, Lawrence (Larry) Florin served as Chief Clinical Officer at Immunicom, Inc., where he led immuno-oncology product development. He also advises various biopharma, medtech, and clinical research organizations.
“We are thrilled to have Larry lead Hesperos at this pivotal time,” said J. Hickman, PhD, Co-founder and Chief Scientist. “His extensive expertise in clinical research and passion for innovation align perfectly with our mission to accelerate the development of safer, more effective therapeutics.”
Larry has played a key role in growing organizations throughout his career, helping secure over $120 million in funding and implementing innovative clinical trials across various therapeutic areas, including pediatric and rare diseases. He also has substantial experience in business development, regulatory strategies, and commercial launches, solidifying his reputation as a leader in life sciences.
“I am excited to join Hesperos during this period of explosive growth in the emerging MPS field,” said Mr. Florin. “With our cutting-edge technology gaining rapid adoption, I’m eager to lead this exceptional team in delivering breakthrough solutions that enhance drug discovery and benefit patients worldwide.”
Mr. Florin holds a BS in biology from Ursinus College and an Executive MBA from Temple University. He frequently speaks at industry conferences and is recognized for leveraging technology to improve patient recruitment, retention, and clinical development efficiency. Under his leadership, Hesperos is well-positioned to continue its growth and innovation as a pioneer in human-based preclinical testing models.
About Hesperos, Inc.
Hesperos is a global contract research organization (CRO) specializing in preclinical drug development through its Human-on-a-Chip® platform. This innovative approach replicates key aspects of human biology, reducing the need for costly and time-consuming animal testing. The Human-on-a-Chip® platform provides meaningful insights that accurately predict an agent’s therapeutic profile while lowering costs and accelerating development timelines.
